{"name":"MabWell Therapeutics","slug":"mabwell","ticker":"Private","exchange":"Private","domain":"mabwell.com","description":"MabWell Therapeutics is a private biopharmaceutical company focused on developing bispecific antibodies for oncology and autoimmune diseases. The company has a pipeline of promising candidates, including its lead product, MW-001, which is currently in Phase 3 clinical trials. With a strong therapeutic focus on cancer and autoimmune disorders, MabWell Therapeutics is well-positioned to capitalize on the growing demand for innovative treatments in these areas.","hq":"Shanghai, China","founded":0,"employees":"","ceo":"Zhihai Liu","sector":"Bispecific Antibodies / Oncology & Autoimmune","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private (~$800M est.)","metrics":{"revenue":15000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"MW-001 patent cliff ($1.5B at risk)","drug":"MW-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"MabWell Therapeutics Announces FDA Fast Track Designation for MW-001","summary":"MabWell Therapeutics received FDA Fast Track designation for its lead product, MW-001, in the treatment of non-Hodgkin lymphoma.","drugName":"MW-001","sentiment":"positive"},{"date":"2023-11-01","type":"earnings","headline":"MabWell Therapeutics Reports Third Quarter 2023 Financial Results","summary":"MabWell Therapeutics reported its third quarter 2023 financial results, with a net loss of $20.5 million and a cash balance of $120 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNc2I5eml1Si1qeGZZdHdCRDl6ZkVUb2tMZ09JU1dOWTdTbWRkYUY4VkpSZWd1dXhxS25YZEFHTzFhc2lWR1Mxd2lhNkRmMS1wMWZuRnBod3NHQXFwUkoyRjNYRVpEUEYzNEVtWXRMUENibVpQcGJnM25xUFp5WXJNWi1YV0k2ZW8?oc=5","date":"2025-09-18","type":"pipeline","source":"Pharmaceutical Technology","summary":"Mabwell and Aditum launch Kalexo Bio for siRNA therapy development - Pharmaceutical Technology","headline":"Mabwell and Aditum launch Kalexo Bio for siRNA therapy development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPbFQ4SVVHTFVtQ0h4NGhwQ1pHOEM4Yk9USGplV0FmTXB6cFpyaEpEeGd1OVN5ZGlfeGZkSmhtSk82VnhqMzVGWFZHTUhaNTM0MDB6eGdfTm9Kd0E2dW1IVkF5V2JmUURrY2oyT3hOZl9FejJYRVV4TDYtbTZ1M2h3bDhPY2EzNm1xYlE?oc=5","date":"2024-09-24","type":"trial","source":"Yahoo Finance","summary":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance","headline":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics S","sentiment":"neutral"}],"patents":[{"drugName":"MW-001","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology","Autoimmune Diseases"],"financials":null,"yahoo":null}